Prestige Consumer Healthcare (NYSE:PBH) Posts Earnings Results, Misses Estimates By $0.16 EPS

Prestige Consumer Healthcare (NYSE:PBH) announced its quarterly earnings results on Wednesday. The company reported $1.23 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16), FiscalAI reports. Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The company had revenue of $281.62 million during the quarter, compared to analysts’ expectations of $293.64 million. Prestige Consumer Healthcare updated its FY 2027 guidance to 4.420-4.510 EPS.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock traded up $1.34 during trading hours on Wednesday, hitting $51.75. 749,860 shares of the stock traded hands, compared to its average volume of 477,998. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. The firm’s 50 day moving average price is $58.79 and its 200-day moving average price is $61.60. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of 13.69, a P/E/G ratio of 1.52 and a beta of 0.40. Prestige Consumer Healthcare has a 1 year low of $49.28 and a 1 year high of $89.37.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total transaction of $66,372.93. Following the sale, the vice president owned 42,820 shares in the company, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.40% of the company’s stock.

Institutional Trading of Prestige Consumer Healthcare

Large investors have recently added to or reduced their stakes in the company. UMB Bank n.a. lifted its holdings in shares of Prestige Consumer Healthcare by 110.1% in the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after buying an additional 219 shares during the period. Danske Bank A S acquired a new position in shares of Prestige Consumer Healthcare in the 3rd quarter valued at about $37,000. Brown Brothers Harriman & Co. acquired a new position in shares of Prestige Consumer Healthcare in the 3rd quarter valued at about $44,000. Geneos Wealth Management Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after buying an additional 269 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its holdings in shares of Prestige Consumer Healthcare by 142.8% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,100 shares of the company’s stock valued at $69,000 after buying an additional 647 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on PBH shares. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Tuesday, April 21st. Oppenheimer dropped their target price on Prestige Consumer Healthcare from $77.00 to $65.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Jefferies Financial Group dropped their target price on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Friday, January 30th. Three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of “Moderate Buy” and a consensus target price of $74.75.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).